Filing Flows › Bolt Biotherapeutics (BOLT) › Q1 2026 › vs Q1 2025
Bolt Biotherapeutics (BOLT) Q1 2026 vs Q1 2025 (year over year)
Bolt Biotherapeutics's revenue fell $1.2M (-98%) from $1.2M in Q1 2025 to $26K in Q1 2026.
Bolt Biotherapeutics, Q1 2026: revenue $26K (-98% year over year), net loss $7.2M, operating cash flow −$8.0M. The chart draws each line against Q1 2025, the increases inside each band.
Every line
| Line | Q1 2026 | Q1 2025 | Change | % |
|---|---|---|---|---|
| Revenue | $26K | $1.2M | −$1.2M | -98% |
| Other income, net | $357K | $1.1M | −$718K | -67% |
| Net loss | $7.2M | $11.0M | −$3.8M | -34% |
| Costs & expenses | $7.6M | $13.3M | −$5.7M | -43% |
| Operating costs | $7.6M | $13.3M | −$5.7M | -43% |
| Research & development | $4.8M | $9.5M | −$4.7M | -49% |
| General & admin | $2.8M | $3.8M | −$1.0M | -27% |
| Operating cash sources | $8.8M | $14.5M | −$5.7M | -39% |
| Depreciation & amortization | $203K | $399K | −$196K | -49% |
| Share-based compensation | $545K | $709K | −$164K | -23% |
| Cash used in operations | $8.0M | $13.4M | −$5.3M | -40% |
| Net loss absorbed | $7.2M | $11.0M | −$3.8M | -34% |
| Working capital & other | $1.5M | $3.4M | −$1.9M | -56% |
Questions
How much did Bolt Biotherapeutics's revenue grow year over year in Q1 2026?
Bolt Biotherapeutics's revenue fell $1.2M (-98%) from $1.2M in Q1 2025 to $26K in Q1 2026.